Aadi Bioscience Announces Publication of Long-Term Efficacy and Safety Data Further Supporting FYARRO® for the Treatment of Malignant PEComa ...Middle East

PR Newswire - News
Aadi Bioscience Announces Publication of Long-Term Efficacy and Safety Data Further Supporting FYARRO® for the Treatment of Malignant PEComa
After 3 years of follow-up in AMPECT trial, confirmed clinically meaningful overall response rate, including multiple patients with complete responses Demonstrated 40 months median duration of response and median survival >53 months Historically, median survival has ranged from 16 to 29...

Read More Details
Finally We wish PressBee provided you with enough information of ( Aadi Bioscience Announces Publication of Long-Term Efficacy and Safety Data Further Supporting FYARRO® for the Treatment of Malignant PEComa )

Apple Storegoogle play

Also on site :